Interstitial irradiation using yttrium-90 (9 OY) rods implanted by needle into the pituitary gland was used as primary treatment in 16 patients with pituitary dependent Cushing's disease. Clinical and biochemical remission was observed within three to six months in 13 and in the
Introduction
As most patients with Cushing's disease (pituitary dependent adrenocorticotrophic hormone hypersecretion associated with bilateral adrenocortical hyperplasia) have an underlying pituitary adenoma,l-4 therapeutic measures should logically be aimed directly at the pituitary. Conventional external irradiation (deep x-ray) to the pituitary fossa has been widely used, but, except for children,5 has been shown to be generally ineffective, with a remission rate of less than 20%.6 Remissions are not only unpredictable after deep x-ray treatment, they may take several months, or even years, to develop, so that additional treatment with drugs is needed to decrease adrenocortical hyperfunction in the interval. The most widely used drug, metyrapone, requires careful monitoring by a specialised endocrine unit, may exacerbate hirsutism, distressing for women,7 and is expensive.
Other irradiation techniques used include heavy-particle treatment in the United States8 and our own past experience with interstitial irradiation9 using yttrium or gold. Both 13 because of encouraging results both in terms of initial remission (75% 94%)' -4 and maintenance of normal pituitary function. We have therefore analysed our experience over the past decade using interstitial irradiation with 9 0Y to assess whether it still has an important role in managing Cushing's disease.
Patients and methods (table)
Between May 1971 and March 1980, we treated 17 patients (4 men, 13 women) with a diagnosis of pituitary dependent Cushing's disease with interstitial irradiation using 90Y as primary pituitary treatment, and this series is consecutive to our initial report using the technique.,9 Clinical and biochemical follow-up has been possible in all but one man who returned abroad two weeks after an uneventful implantation. The ages of the remaining 16 patients at referral ranged from 12 to 54 (mean 33 8) and the duration of history from one to 10 years (mean 3*4).
The diagnosis was based in 15 patients on all of the following biochemical criteria: (1) persistently raised concentrations of urinary free cortisol; (2) abnormally raised midnight serum cortisol concentrations; (3) detectable concentrations of plasma adrenocorticotrophic hormone (in the 13 in whom this hormone was measured); (4) a fall in urinary free cortisol or urine 17-oxogenic steroids, or both, by at least half the basal value after taking dexamethasone (2 mg 8-hourly for three days); and (5) (table) Long-term follow-up ranged from 6 to 123 months (mean 39) from the time of the definitive implantation procedure. At the last follow-up, all patients had urinary free cortisol excretion rates within the normal range, apart from the three who are still clinically dependent on corticosteroids. Of 12 non-corticosteroid-dependent patients studied both before and after operation, a diurnal cortisol rhythm, with values within our laboratory reference range, has returned in 10. Some form of permanent pituitary hormone replacement therapy has been needed in six patients, all of whom had at least 150 kilorads irradiation, and the three who required a supplementary implant. Three have needed replacement corticosteroids, of whom two also required sex steroids, one also thyroxine, and one desmopressin because of persistent diabetes insipidus. Two other patients have required only thyroxine, which became evident at 12 and 54 months post-implant respectively, and the sixth patient needed sex steroids.
Normal gonadal function, judged in men by restored potency and normal testosterone values, and in premenopausal women by a regular menstrual cycle with normal plasma oestradiol, was maintained in all three men, and in five of the eight premenopausal women, including one (case 2) who has had two full-term pregnancies two and five years after her implant procedure.
An impaired gonadotrophin response to luteinising hormonereleasing hormone (100 ,sg) was shown in two of three premenopausal women (cases 12 and 15) with persistent amenorrhoea post-implantation. Both had received at least 150 kilorads of interstitial irradiation. Gonadotrophin responses after the releasing hormone remain normal in the other premenopausal women tested. Marginally but inappropriately raised serum prolactin concentrations were found in two patients at last follow-up, both of whom were normoprolactinaemic before implant (cases 11 and 16).
The thyroid-stimulating hormone response to thyrotrophinreleasing hormone (200 sLg) remains normal in nine of the 10 patients tested and not requiring thyroxine, and slightly reduced in one (case 7).
Discussion
All patients treated with 90Y for Cushing's disease achieved a clinical and biochemical remission without postoperative morbidity and in none has there been evidence of recurrence at last follow-up. While excellent initial remission rates have been reported using selective transsphenoidal hypophysectomy,l-4 recurrent disease has been observed in all but one large series and, in this latter study,' follow-up was patients studied, while in two surgical series reporting similar data the figures were six out of seven and five out of nine patients respectively. ' While the absence of a normal diurnal rhythm in two implanted patients suggests that their tumour has been incompletely destroyed, they remain clinically well and have normal 24-h urinary free cortisol secretion rates. We suppose that the remaining tumour mass is insufficient to induce hypercortisolism and that the effect of interstitial irradiation is protective against further tumour growth. Of 20 patients in our initial series9 who obtained a remission with 90Y only, none has relapsed in the subsequent 10 years of follow-up.
Maintenance of normal pituitary function is also important in assessing the overall efficacy of treatment. A third of our patients have required some form of permanent replacement treatment after implantation, but were only those receiving the highest irradiation doses. This proportion is considerably less than that observed after total hypophysectomyl but is higher than that reported after selective adenomectomy.' 34Nevertheless, gonadal function was preserved in all men and most premenopausal women. We have previously shown a pronounced improvement in the gonadotrophin response to the releasing hormone (LHRH) in women with Cushing's disease going into remission after implantation.'9 The same finding also applies to all premenopausal women in the present series not receiving the highest irradiation doses, and had been maintained at last follow-up.
This series shows a considerable improvement in remission rate and reduction in hypopituitarism compared with our initial report published almost a decade ago 9 for several reasons. Firstly, our experience indicated that the higher local intrapituitary dose of irradiation obtained using the f-emitter 90Y was more successful in inducing and then maintaining a remission than that obtained using the lower but more wide-ranging dose of irradiation from the y-emitter 198Au. Secondly, experience had shown that if a tumour was large enough to deform the sella, a high dose of irradiation was essential, and this policy has been applied in the current series. Thirdly, no patients in this series presented with evidence of extrasellar tumour invasion, a condition in which interstitial irradiation is unlikely to be curative. 9 Surgery may similarly be unsuccessful in such cases.3 11 Finally, the lack of any perioperative complications may relate to increased experience with the technique.
In conclusion, our results indicate that interstitial irradiation with 9OY is valuable for patients with Cushing's disease and compares favourably with the best results obtained after selective transsphenoidal hypophysectomy. Remission after a single therapeutic intervention in patients with a normal pituitary fossa at presentation has not as yet been associated with the need for long-term replacement therapy for up to a period of 10 years of follow-up. In patients who are seen with an already enlarged pituitary fossa, however, the increased dose of irradiation administered, while able to effect a complete cure, is likely to result in the need for some form of long-term pituitary replacement. This is also true for patients without an enlarged fossa requiring a second implant. - There have been several claims that visual display units may produce symptoms in the skin of operators. The evidence is far from firm, however, and such experimental studies that have been performed have not come up with any ideas about underlying aetiology. The possibilities are that it is: (a) a radiative effect of the "optical radiation" emitted by the screen; (b) somehow due to static electricity associated with the unit; (c) of psychological origin. The first option seems most unlikely for Cox (in a paper given at a conference at Loughborough University, 1980) and many others have made extensive radiation measurements on visual display units, and no hazard can be detected. The static charge around a visual display unit may be relatively high, but hardly anything is known about how to connect this convincingly with skin symptoms. The suspicion that psychological causes may be important rests on the surmise that the sufferers have nearly all been young women, possibly bored with their job. (For details see the paper by Nilsen,' who gives full references, and a letter by Linden and Rolfsen,' who attempt to make a case for blaming static electricity.) Whatever its cause, if this condition is real visual display unit occupational dermatitis seems to be rare, and it is not possible to suggest any preventive measures. 
